Aripiprazole increases NADPH level in PC12 cells

The role of NADPH oxidase

Hiroshi Nagasaki, Akira Nakashima, Yoko S. Kaneko, Yu Kodani, Takeshi Takayanagi, Mitsuyasu Itoh, Kazunao Kondo, Toshiharu Nagatsu, Yoji Hamada, Miyuki Ota, Akira Ota

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In aripiprazole-treated PC12 cells, we previously showed that the mitochondrial membrane potential (Δψm) was rather increased in spite of lowered cytochrome c oxidase activity. To address these inconsistent results, we focused the NADPH generation by glucose-6-phosphate dehydrogenase (G6PD), a rate-limiting enzyme of the pentose phosphate pathway (PPP), to titrate reactive oxygen species (ROS) that results in the Δψm maintenance. G6PD may be also involved in another inconsistent result of lowered intracellular lactate level in aripiprazole-treated PC12 cells, because PPP competes glucose-6-phosphate with the glycolytic pathway, resulting in the downregulation of glycolysis. Therefore, we assayed intracellular amounts of NADPH, ROS, and the activities of the enzymes generating or consuming NADPH (G6PD, NADP+-dependent isocitrate dehydrogenase, NADP+-dependent malic enzyme, glutathione reductase, and NADPH oxidase [NOX]) and estimated glycolysis in 50 μM aripiprazole-, clozapine-, and haloperidol-treated PC12 cells. NADPH levels were enhanced only in aripiprazole-treated ones. Only haloperidol increased ROS. However, the enzyme activities did not show significant changes toward enhancing NADPH level except for the aripiprazole-induced decrease in NOX activity. Thus, the lowered NOX activity could have contributed to the aripiprazole-induced increase in the NADPH level by lowering ROS generation, resulting in maintained Δψm. Although the aforementioned assumption was invalid, the ratio of fructose-1,6-bisphosphate to fructose-6-phosphate was decreased by all antipsychotics examined. Pyruvate kinase activity was enhanced only by aripiprazole. In summary, these observations indicate that aripiprazole possibly possesses the pharmacological superiority to clozapine and haloperidol in the ROS generation and the adjustment of glycolytic pathway.

Original languageEnglish
Pages (from-to)91-103
Number of pages13
JournalJournal of Neural Transmission
Volume121
Issue number1
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

NADPH Oxidase
PC12 Cells
NADP
Reactive Oxygen Species
Glucosephosphate Dehydrogenase
Haloperidol
Pentose Phosphate Pathway
Clozapine
Glycolysis
malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+)
Enzymes
Glucose-6-Phosphate
Pyruvate Kinase
Aripiprazole
Glutathione Reductase
Mitochondrial Membrane Potential
Electron Transport Complex IV
Antipsychotic Agents
Lactic Acid
Down-Regulation

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Nagasaki, Hiroshi ; Nakashima, Akira ; Kaneko, Yoko S. ; Kodani, Yu ; Takayanagi, Takeshi ; Itoh, Mitsuyasu ; Kondo, Kazunao ; Nagatsu, Toshiharu ; Hamada, Yoji ; Ota, Miyuki ; Ota, Akira. / Aripiprazole increases NADPH level in PC12 cells : The role of NADPH oxidase. In: Journal of Neural Transmission. 2014 ; Vol. 121, No. 1. pp. 91-103.
@article{1e436ac84e4a41ab9d55bf5a68d6a949,
title = "Aripiprazole increases NADPH level in PC12 cells: The role of NADPH oxidase",
abstract = "In aripiprazole-treated PC12 cells, we previously showed that the mitochondrial membrane potential (Δψm) was rather increased in spite of lowered cytochrome c oxidase activity. To address these inconsistent results, we focused the NADPH generation by glucose-6-phosphate dehydrogenase (G6PD), a rate-limiting enzyme of the pentose phosphate pathway (PPP), to titrate reactive oxygen species (ROS) that results in the Δψm maintenance. G6PD may be also involved in another inconsistent result of lowered intracellular lactate level in aripiprazole-treated PC12 cells, because PPP competes glucose-6-phosphate with the glycolytic pathway, resulting in the downregulation of glycolysis. Therefore, we assayed intracellular amounts of NADPH, ROS, and the activities of the enzymes generating or consuming NADPH (G6PD, NADP+-dependent isocitrate dehydrogenase, NADP+-dependent malic enzyme, glutathione reductase, and NADPH oxidase [NOX]) and estimated glycolysis in 50 μM aripiprazole-, clozapine-, and haloperidol-treated PC12 cells. NADPH levels were enhanced only in aripiprazole-treated ones. Only haloperidol increased ROS. However, the enzyme activities did not show significant changes toward enhancing NADPH level except for the aripiprazole-induced decrease in NOX activity. Thus, the lowered NOX activity could have contributed to the aripiprazole-induced increase in the NADPH level by lowering ROS generation, resulting in maintained Δψm. Although the aforementioned assumption was invalid, the ratio of fructose-1,6-bisphosphate to fructose-6-phosphate was decreased by all antipsychotics examined. Pyruvate kinase activity was enhanced only by aripiprazole. In summary, these observations indicate that aripiprazole possibly possesses the pharmacological superiority to clozapine and haloperidol in the ROS generation and the adjustment of glycolytic pathway.",
author = "Hiroshi Nagasaki and Akira Nakashima and Kaneko, {Yoko S.} and Yu Kodani and Takeshi Takayanagi and Mitsuyasu Itoh and Kazunao Kondo and Toshiharu Nagatsu and Yoji Hamada and Miyuki Ota and Akira Ota",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00702-013-1075-0",
language = "English",
volume = "121",
pages = "91--103",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "1",

}

Nagasaki, H, Nakashima, A, Kaneko, YS, Kodani, Y, Takayanagi, T, Itoh, M, Kondo, K, Nagatsu, T, Hamada, Y, Ota, M & Ota, A 2014, 'Aripiprazole increases NADPH level in PC12 cells: The role of NADPH oxidase', Journal of Neural Transmission, vol. 121, no. 1, pp. 91-103. https://doi.org/10.1007/s00702-013-1075-0

Aripiprazole increases NADPH level in PC12 cells : The role of NADPH oxidase. / Nagasaki, Hiroshi; Nakashima, Akira; Kaneko, Yoko S.; Kodani, Yu; Takayanagi, Takeshi; Itoh, Mitsuyasu; Kondo, Kazunao; Nagatsu, Toshiharu; Hamada, Yoji; Ota, Miyuki; Ota, Akira.

In: Journal of Neural Transmission, Vol. 121, No. 1, 01.01.2014, p. 91-103.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aripiprazole increases NADPH level in PC12 cells

T2 - The role of NADPH oxidase

AU - Nagasaki, Hiroshi

AU - Nakashima, Akira

AU - Kaneko, Yoko S.

AU - Kodani, Yu

AU - Takayanagi, Takeshi

AU - Itoh, Mitsuyasu

AU - Kondo, Kazunao

AU - Nagatsu, Toshiharu

AU - Hamada, Yoji

AU - Ota, Miyuki

AU - Ota, Akira

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In aripiprazole-treated PC12 cells, we previously showed that the mitochondrial membrane potential (Δψm) was rather increased in spite of lowered cytochrome c oxidase activity. To address these inconsistent results, we focused the NADPH generation by glucose-6-phosphate dehydrogenase (G6PD), a rate-limiting enzyme of the pentose phosphate pathway (PPP), to titrate reactive oxygen species (ROS) that results in the Δψm maintenance. G6PD may be also involved in another inconsistent result of lowered intracellular lactate level in aripiprazole-treated PC12 cells, because PPP competes glucose-6-phosphate with the glycolytic pathway, resulting in the downregulation of glycolysis. Therefore, we assayed intracellular amounts of NADPH, ROS, and the activities of the enzymes generating or consuming NADPH (G6PD, NADP+-dependent isocitrate dehydrogenase, NADP+-dependent malic enzyme, glutathione reductase, and NADPH oxidase [NOX]) and estimated glycolysis in 50 μM aripiprazole-, clozapine-, and haloperidol-treated PC12 cells. NADPH levels were enhanced only in aripiprazole-treated ones. Only haloperidol increased ROS. However, the enzyme activities did not show significant changes toward enhancing NADPH level except for the aripiprazole-induced decrease in NOX activity. Thus, the lowered NOX activity could have contributed to the aripiprazole-induced increase in the NADPH level by lowering ROS generation, resulting in maintained Δψm. Although the aforementioned assumption was invalid, the ratio of fructose-1,6-bisphosphate to fructose-6-phosphate was decreased by all antipsychotics examined. Pyruvate kinase activity was enhanced only by aripiprazole. In summary, these observations indicate that aripiprazole possibly possesses the pharmacological superiority to clozapine and haloperidol in the ROS generation and the adjustment of glycolytic pathway.

AB - In aripiprazole-treated PC12 cells, we previously showed that the mitochondrial membrane potential (Δψm) was rather increased in spite of lowered cytochrome c oxidase activity. To address these inconsistent results, we focused the NADPH generation by glucose-6-phosphate dehydrogenase (G6PD), a rate-limiting enzyme of the pentose phosphate pathway (PPP), to titrate reactive oxygen species (ROS) that results in the Δψm maintenance. G6PD may be also involved in another inconsistent result of lowered intracellular lactate level in aripiprazole-treated PC12 cells, because PPP competes glucose-6-phosphate with the glycolytic pathway, resulting in the downregulation of glycolysis. Therefore, we assayed intracellular amounts of NADPH, ROS, and the activities of the enzymes generating or consuming NADPH (G6PD, NADP+-dependent isocitrate dehydrogenase, NADP+-dependent malic enzyme, glutathione reductase, and NADPH oxidase [NOX]) and estimated glycolysis in 50 μM aripiprazole-, clozapine-, and haloperidol-treated PC12 cells. NADPH levels were enhanced only in aripiprazole-treated ones. Only haloperidol increased ROS. However, the enzyme activities did not show significant changes toward enhancing NADPH level except for the aripiprazole-induced decrease in NOX activity. Thus, the lowered NOX activity could have contributed to the aripiprazole-induced increase in the NADPH level by lowering ROS generation, resulting in maintained Δψm. Although the aforementioned assumption was invalid, the ratio of fructose-1,6-bisphosphate to fructose-6-phosphate was decreased by all antipsychotics examined. Pyruvate kinase activity was enhanced only by aripiprazole. In summary, these observations indicate that aripiprazole possibly possesses the pharmacological superiority to clozapine and haloperidol in the ROS generation and the adjustment of glycolytic pathway.

UR - http://www.scopus.com/inward/record.url?scp=84892673021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892673021&partnerID=8YFLogxK

U2 - 10.1007/s00702-013-1075-0

DO - 10.1007/s00702-013-1075-0

M3 - Article

VL - 121

SP - 91

EP - 103

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 1

ER -